(Q35313371)

English

Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish La

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish La (English)

1 reference

Europe PubMed Central

7 August 2017

1 reference

based on heuristic

inferred from title

author name string

Nordmann JP

1

1 reference

Europe PubMed Central

7 August 2017

Söderström M

2

1 reference

Europe PubMed Central

7 August 2017

Rouland JF

3

1 reference

Europe PubMed Central

7 August 2017

Malecaze F

4

1 reference

Europe PubMed Central

7 August 2017

language of work or name

0 references

publication date

1 February 2000

1 reference

Europe PubMed Central

7 August 2017

British Journal of Ophthalmology

1 reference

Europe PubMed Central

7 August 2017

84

1 reference

Europe PubMed Central

7 August 2017

2

1 reference

Europe PubMed Central

7 August 2017

181-185

1 reference

Europe PubMed Central

7 August 2017

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

12 July 2018

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

12 July 2018

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

12 July 2018

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

12 July 2018

Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

12 July 2018

Long-term evaluation of timolol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

12 July 2018

Long-Term Experience with Timolol Ophthalmic Solution in Patients with Open-Angle Glaucoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

12 July 2018

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

26 September 2018

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1723381

26 September 2018

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://pubmed.ncbi.nlm.nih.gov/10655195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://pubmed.ncbi.nlm.nih.gov/10655195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of withdrawal of timolol in chronically treated glaucoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10655195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Timolol-pilocarpine combined vs timolol and pilocarpine given separately

1 reference

https://pubmed.ncbi.nlm.nih.gov/10655195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10655195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BJO.84.2.181

1 reference

Europe PubMed Central

7 August 2017

release_xcuzdsmb7jcchgbhtl5boetbae

1 reference

https://api.fatcat.wiki/v0/release/xcuzdsmb7jcchgbhtl5boetbae

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35313371&oldid=1844814426"